• en
  • it
  • de
  • Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    More News and Fairs

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint

    UPDATE 4: IMPACT OF THE CURRENT COVID-19 OUTBREAK ON INDIAN PRODUCTION SITES

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to

    FarmaBios activities are regularly proceeding…

    During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part

    Farmabios Breaks Ground to Expand its Manufacturing Footprint in Gropello Cairoli (Italy)

    As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].

    Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios